0001140361-14-031231.txt : 20140807
0001140361-14-031231.hdr.sgml : 20140807
20140807151022
ACCESSION NUMBER: 0001140361-14-031231
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140805
FILED AS OF DATE: 20140807
DATE AS OF CHANGE: 20140807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avalanche Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1035 O?BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 1035 O?BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MCLAUGHLIN JOHN PETER
CENTRAL INDEX KEY: 0001277967
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 141023462
MAIL ADDRESS:
STREET 1: C/O PDL BIOPHARMA, INC.
STREET 2: 932 SOUTHWOOD BOULEVARD
CITY: INCLINE VILLAGE
STATE: NV
ZIP: 89451
4
1
doc1.xml
FORM 4
X0306
4
2014-08-05
0
0001501756
Avalanche Biotechnologies, Inc.
AAVL
0001277967
MCLAUGHLIN JOHN PETER
C/O AVALANCHE BIOTECHNOLOGIES, INC.
1035 O'BRIEN DRIVE, SUITE A
MENLO PARK
CA
94025
1
0
0
0
Common Stock
2014-08-05
4
C
0
13280
A
13280
I
See Footnote
Common Stock
2014-08-05
4
C
0
13280
A
13280
I
See Footnote
Series B Preferred Stock
2014-08-05
4
C
0
13280
D
Common Stock
13280
0
I
See Footnote
Series B Preferred Stock
2014-08-05
4
C
0
13280
D
Common Stock
13280
0
I
See Footnote
Each share of Series A Preferred and Series B Preferred Stock automatically converted into one share of Issuer's Common Stock upon the consummation of the Issuer's initial public offering (the "IPO").
The shares are held directly by the John Peter McLaughlin 2014 Irrevocable Trust.
The shares are held directly by the Christopher James McLaughlin 2014 Irrevocable Trust.
The Series A Preferred and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1:1 basis upon the completion of Issuer's IPO.
The expiration date is not relevant to the conversion of these securities.
/s/ Michael Swartzburg, Attorney-in-Fact for John McLaughlin
2014-08-07